Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004441 · ClinicalTrials.gov registry record · NA
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT00004441 is a NA study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 39 participants.
The verdict
NCT00004441, a NA study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and fat-soluble vitamin status in these patients.
Interventions
- DRUG tauroursodeoxycholic acid
- DRUG ursodiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1997-09 |
| Est. Completion | 2001-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004441
The ClinicalTrials.gov registry entry for NCT00004441 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tauroursodeoxycholic acid is the first listed.
NCT00004441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004441 about?
NCT00004441 is a clinical study titled "Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis". OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects on biliary bile acid com...
What is the current status of trial NCT00004441?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 1997-09. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00004441?
The interventions under investigation include: tauroursodeoxycholic acid (DRUG), ursodiol (DRUG).
Who is sponsoring clinical trial NCT00004441?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.